**September 03, 2026**

To,
Corporate Services Department,
BSE Ltd.,
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai- 400001

Dear Sir,

**Sub: Outcome of Meeting of the Board of Directors of Titan Biotech Limited (the Company) held on September 3, 2026**

In terms of the requirements of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circulars, as amended from time to time, this is to inform you that the Board of Directors at its meeting held today, i.e. Thursday, September 03, 2026, has, *inter- alia:*

A. **Considered and approved the issuance of Bonus shares to the Equity shareholders of the Company.**

Issue of bonus equity shares in the ratio of 1:4 i.e. 1(one) new fully paid-up bonus equity shares of Rs. 2/- each for every 4 (Four) existing fully paid-up equity shares of Rs. 2/- each held by the members as on the record date, subject to the members approval in forthcoming Annual General Meeting of the company.

The Record Date for the purpose of determining the equity shareholders of the Company eligible for bonus equity shares of the Company will be informed in due course of time.

Details with respect to bonus issue of shares of the Company in as required to be disclosed under Regulation 30 read with Schedule III of the Listing Regulations and the disclosure pursuant to SEBI Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated 30th January, 2026, is enclosed as "**Annexure- A**".

**B. Considered and approved the Increase in the Authorised Share Capital of the Company and amendment in Capital Clause of the Memorandum of Association.**

Increase the Authorized Share Capital of the Company from existing Rs. 10,00,00,000/- (Rupees Ten Crore) divided into 5,00,00,000 (Five Crore) Equity Shares of Rs. 2/- (Rupees Two) each to Rs. 10,40,00,000/- (Rupees Ten Crore and Forty Lakhs) divided into 5,20,00,000 (Five Crore and Twenty Lakhs) Equity Shares of Rs. 2/- (Rupees Two) each to rank pari-passu with the existing Equity Shares of the Company and thereby consequent alteration of Clause V to the Memorandum of Association of the Company, subject to the approval of shareholders to be obtained in the forthcoming Annual General Meeting and such other approvals as may be required.

The disclosure pursuant to SEBI Listing Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated 30th January, 2026, is enclosed as **"Annexure B".**

**C. Recommendation of the re-appointment of Mr. Rohit Jain (DIN: 07191154), as an Independent Director of the company for a second term of five consecutive years w.e.f. September 30, 2026**

Based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the re-appointment of Mr. Rohit Jain (DIN: 07191154) as an Independent Director of the Company for a further term of five consecutive years, from September 30, 2026 to September 29, 2031, subject to the approval of the shareholders.

The requisite disclosures under Regulation 30 of the SEBI Listing Regulations, read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are provided in Annexure-C.

**D. Annual General Meeting**

Please be informed that the **Thirty-Fourth (34th) Annual General Meeting** ("**AGM**") of the Company has been scheduled for **Tuesday, September 29, 2026**, through Video Conferencing ("VC")/Other AudioVisual Means ("OAVM").

Annual Report and Notice of the AGM shall be sent in due course. The same shall also be uploaded on the Company's website.

**E. Cut-off Date**

The Company has fixed **Tuesday, September 22, 2026** as the "Cut-off Date" for the purpose of determining the members eligible to vote on the resolutions set out in the Notice of the AGM.

**F. Record Date**

As informed by the Company on May 30, 2026, Board of Directors has recommended a final dividend of Rs. 0.50/- (Rupees Fifty Paisa Only) per shares. The record date for the purpose of the Annual General Meeting and payment of dividend is **Tuesday, September 22, 2026.**

**G. Book Closure date**

The Company has fixed Book Closure date from **Wednesday, September 23, 2026 to Tuesday, September 29, 2026** (both days inclusive).

The meeting of Board of Directors commenced at **11:30 A.M. and concluded at 12:05 P.M**.

The above information will be available on the website of the company i.e www.titanbiotechltd.com and BSE Ltd i.e www.bseindia.com.

Request to kindly take this information on record and acknowledge.

**For and on behalf of**
**Titan Biotech Limited**
CHARANJIT SINGH
Digitally signed by CHARANJIT SINGH
Date: 2026.09.03 12:10:24 +05'30'
**Charanjit Singh**
**Company Secretary & Compliance Officer**
**M.No A12726**
**Encl: As above**

**Annexure-A**

**DISCLOSURE UNDER REGULATION 30 OF SEBI LISTING REGULATIONS READ WITH SEBI MASTER CIRCULAR ISSUED ON JULY 11, 2023 AND LAST UPDATED ON JANUARY 30, 2026 BEARING REFERENCE NO. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 ("SEBI CIRCULAR")**

<table>
<tr><th>S.No</th><th>Particulars</th><th>Details</th></tr>
<tr><td>i.</td><td>Types of Securities proposed to be issued (viz. equity shares, convertibles etc.)</td><td>Equity Shares</td></tr>
<tr><td>ii.</td><td>Type of issuance (further public offering rights issue, depository receipts (ADR / GDR), qualified institutions placement, preferential allotment etc.)</td><td>Bonus Issue</td></tr>
<tr><td>iii.</td><td>Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)</td><td>1,03,29,625 Shares</td></tr>
<tr><td>iv.</td><td>whether bonus is out of free reserves created out of profits or share premium account;</td><td>Bonus shares will be issued out of Securities Premium account and/or retained earnings and/or free reserves and/or any other permitted reserves/surplus of the Company available as at March 31, 2026.</td></tr>
<tr><td>v.</td><td>bonus ratio</td><td>1:4 i.e. 1 (One) Equity Shares for every 4 (Four) existing Equity Shares held as on a record date.</td></tr>
<tr><td>vi.</td><td colspan="2">Details of share capital – pre and post bonus issue (after giving effect to split adjustment)
<table>
<tr><th>Particulars</th><th colspan="3">Pre Bonus</th><th colspan="3">Post Bonus</th></tr>
<tr><th>Equity Shares</th><th>No. of shares</th><th>Face Value (Rs.)</th><th>Total Share Capital (Rs.)</th><th>No. of shares</th><th>Face Value (Rs.)</th><th>Total Share Capital (Rs.)</th></tr>
<tr><td>Authorised Share Capital</td><td>5,00,00,000</td><td>2</td><td>10,00,00,000</td><td>5,20,00,000</td><td>2</td><td>10,40,00,000</td></tr>
<tr><td>Paid-up Capital</td><td>4,13,18,500</td><td>2</td><td>8,26,37,000</td><td>5,16,48,125</td><td>2</td><td>10,32,96,250</td></tr>
<tr><td>Subscribed capital</td><td>4,13,18,500</td><td>2</td><td>8,26,37,000</td><td>5,16,48,125</td><td>2</td><td>10,32,96,250</td></tr>
</table></td></tr>
<tr><td>vii.</td><td>free reserves and/ or share premium required for implementing the bonus issue</td><td>Rs. 2,06,59,250 is required for implementing the Bonus Issue.</td></tr>
</table>

| | | |
|---|---|---|
| viii. | **free reserves and/ or share premium available for capitalization and the date as on which such balance is available** | As on 31st March, 2026, balance of Free reserves and/ or share premium available for capitalization is 16,257.78 Lacs |
| ix. | **whether the aforesaid figures are audited** | Yes, the aforesaid figure is as per the audited financial statements. |
| x. | **estimated date by which such bonus shares would be credited/dispatched** | The Bonus shares will be credited/dispatched within 2 months from the date of Board's approval i.e. on or before November 03, 2026 subject to necessary approvals. |

CHARANJIT SINGH
Digitally signed by CHARANJIT SINGH
Date: 2026.09.03 12:10:38 +05'30'

**Annexure B**

**DISCLOSURE UNDER REGULATION 30 OF SEBI LISTING REGULATIONS READ WITH SEBI MASTER CIRCULAR ISSUED ON JULY 11, 2023 AND LAST UPDATED ON JANUARY 30, 2026 BEARING REFERENCE NO. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 ("SEBI CIRCULAR")**

| Existing Clause 5 | Proposed Clause 5 |
|---|---|
| The existing Clause (5) of Memorandum of Association of the Company:<br><br>*"5. The Authorised Share Capital of the Company is Rs. 10,00,00,000 (Ten Crore) divided into 5,00,00,000 (Five Crore) equity shares of Rs. 2/- each."* | The existing Clause (5) of Memorandum of Association of the Company be and is hereby amended by substituting with the following clause:<br><br>***"5. The Authorised Share Capital of the Company is Rs. 10,40,00,000 (Ten Crore and Forty Lakhs) divided into 5,20,00,000 (Five Crore and Twenty Lakhs) equity shares of Rs. 2/- each."*** |

CHARANJIT SINGH
Digitally signed by CHARANJIT SINGH
Date: 2026.09.03 12:10:48 +05'30'

**Office: 903-909. 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India**
**Telephone no.: 011-27355742, 71239900(44 Lines), CIN: L74999RJ1992PLC013387**

**Annexure-C**

**Details under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations, 2015") read with SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are given below:**

| S.No | Particulars | Details |
|---|---|---|
| 1. | Name of Director | **Mr. Rohit Jain** |
| 2. | Reason for change viz. ~~appointment~~, Re-appointment; ~~resignation; removal, death or otherwise~~ | Re-appointment as Independent Director(s) for a second term of five consecutive years commencing from September 30, 2026 to September 29, 2031, subject to approval of the Shareholders of the Company. |
| 3. | Date of ~~appointment~~/re-appointment/~~cessation (as applicable)~~ | Date of Re-appointment- September 30, 2026 |
| 4. | terms of ~~appointment~~ / re-appointment | Re-appointment as an Independent Director for a second term of five consecutive years commencing from September 30, 2026 to September 29, 2031, not liable to retire by rotation. |
| 5. | Brief profile (in case appointment) | Mr. Rohit Jain is an Independent Director of the Company with over 12 years of professional experience. He is currently a Partner at Singhania & Co. LLP and has previously worked with Amarchand & Mangaldas & Suresh A. Shroff & Co., OrthoHeal Pvt. Ltd., Ben & Gaws Private Limited, Shri JJT University, PadUp Ventures, and IIM Calcutta Innovation Park. He brings diverse experience across legal, corporate, advisory and professional services. |
| 6. | disclosure of relationships between directors (in case of appointment of a director | Mr. Rohit Jain is not related to any of the Director of the Company. |
| 7. | Shareholding, if any in company | NIL |
| 8. | Name of listed entities in which the resigning Director holds directorship | Not Applicable |
| 9. | Information as required under BSE circular Number LIST/COM/14/2018-19 and NSE circular no. NSE/CML/2018/24 dated June 20, 2018 | Mr. Rohit Jain is not debarred from holding the office of director by virtue of any order of SEBI or any other authority. |

CHARANJIT SINGH
Digitally signed by CHARANJIT SINGH
Date: 2026.09.03 12:10:59 +05'30'